Acute Graft-Versus-Host Disease

  • Susan Slater
Chapter
First Online:

Abstract

Despite advances in HLA typing, acute GvHD remains a leading cause of morbidity and mortality among allogeneic transplant recipients. It is estimated that 30–50% of patients who receive stem cell products from HLA-identical siblings will develop grades 2–4 GvHD, while rates of GvHD in matched unrelated donor transplants are estimated to be between 50 and 70%. Acute GvHD has historically been defined as occurring prior to day +100 and chronic GvHD as occurring after day +100. However, recently there has been a move to define GvHD based on the clinical symptoms and pathologic findings rather than by an arbitrary timeline. The outcome of acute GvHD is dependent on the overall grade of GvHD and the patient’s response to initial treatment.

Keywords

Conditioning Regimen Acute GvHD Progressive Multifocal Leukoencephalopathy Capillary Leak Syndrome Elevated Alkaline Phosphatase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Alousi, A., Weisdorf, D., Logan, B., Bolanos-Meade, J., Carter, S., DiFronzo, N., et al. (2009). Etanercept, mycophenlate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: A randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood, 114:511–517.CrossRefPubMedGoogle Scholar
  2. Antin, J., Chen, A., Couriel, D., Ho, V., Nash, R., Weisdorf, D. (2004). Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant, 10:655–668.CrossRefPubMedGoogle Scholar
  3. Bay, J., Dhedin, N., Goerner, M., Vannier, J., Marie-Cardine, A., Stamatoullas, A., et al. (2005). Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Retrospective analysis and comparison of other interleukin-2 receptor antibodies. Transplantation, 80:782–788.CrossRefPubMedGoogle Scholar
  4. Bertz, H., Afting, M., Kreisel, W., Duffner, U., Greinwalkd, R., Finke, J. (1999). Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant, 24:1185–1189.Google Scholar
  5. Bolanos-Meade, J., Jacobsohn, D., Margolis, J., Ogden, A., Wientjes, M., Byrd, J., et al. (2005). Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol, 23:2661– 2668.CrossRefPubMedGoogle Scholar
  6. Cahn, J., Klein, J., Lee, S., Milpied, N., Blaise, D., Antin, J., et al. (2005). Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems; a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI) and International Transplant Registry (IBMTR) prospective study. Blood, 106:1495–1500.CrossRefPubMedGoogle Scholar
  7. Deeg, H. (2007). How I treat refractory acute GVHD. Blood, 109:4119–4126.CrossRefPubMedGoogle Scholar
  8. Devergie, A. (2008). Graft versus host disease. In Haematopoietic Stem Cell Transplantation: The EBMT Handbood (pp. 218–234).Google Scholar
  9. Drobyski, W., Hari, P., Keever-Taylor, C., Komorowski, R., Grossman, W. (2009). Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant, 43:169–177.CrossRefPubMedGoogle Scholar
  10. Duarte, R., Delgado, J., Shaw, B., Wrench, D., Ethell, M., Patch, D., et al. (2005). Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. Biol Blood Marrow Transplant, 11:805–813.CrossRefPubMedGoogle Scholar
  11. Ferrera, J. (2008). Advances in the clinical management of GVHD. Best Pract Res Clin Haematol, 21:677–682.CrossRefGoogle Scholar
  12. Ferrera, J., Levine, J., Reddy, P., Holler, E. (2009). Graft-versus-host disease. Lancet, 373:1550– 1561.CrossRefGoogle Scholar
  13. Funke, V., de Mederios, C., Setubal, D., Ruiz, J., Bitencourt, M., Bonfim, C., et al. (2006). Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Trasplant, 37:961–965.CrossRefGoogle Scholar
  14. Ghez, D., Rubio, M., Maillard, N., Suarez, F., Chandesris, M., Delarue, R., et al. (2009). Rapamycin for refractory acute graft-versus-host disease. Transplantation, 88:1081–1087.CrossRefPubMedGoogle Scholar
  15. Greinix, H., Volc-Platzer, B., Knobler, R. (2000). Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease. Leukemia Lymphoma, 36:425–434.CrossRefPubMedGoogle Scholar
  16. Hess, A. (2010). Reconstitution of self-tolerance after hematopoietic stem cell transplantation. Immunol Res, 47:143–152.CrossRefPubMedGoogle Scholar
  17. Hoda, D., Pidala, J., Salgado-Vila, N., Kim, J., Perkins, J., Bookout, R., et al. (2009). Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant, 45:1–5.Google Scholar
  18. Holmberg, L., Kikuchi, K., Gooley, T., Adams, K., Hockenbery, D., Flowers, M., et al. (2006). Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: Incidence, risk factors and outcome. Biol Blood Marrow Transplant, 12:226–234.CrossRefPubMedGoogle Scholar
  19. Ibrahim, R., Abidi, M., Cronin, S., Lum, L., Al-Kadhimi, Z., Ratanatharathorn, V., et al. (2009). Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant, 15:395–405.CrossRefPubMedGoogle Scholar
  20. Jacobsohn, D., Vogelsang, G. (2007). Acute graft versus host disease. Orphanet J Rare Diseases 2.Google Scholar
  21. Johnson, M., Farmer, E. (1998). Graft-versus-host disease reactions in dermatology. J Am Acad Dermatol, 38:369–396.CrossRefPubMedGoogle Scholar
  22. Kim, S. (2007). Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. Ann Pharmacother, 41:1436–1444.CrossRefPubMedGoogle Scholar
  23. Kuykendall, T., Smoller, B. (2003). Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone marrow transplantation. J Am Acad Dermatol, 49:1081–1085.CrossRefPubMedGoogle Scholar
  24. Levine, J., Paczesny, S., Mineishi, S., Braun, T., Choi, S., Hutchinson, R., et al. (2008). Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood, 111:2470–2475.CrossRefPubMedGoogle Scholar
  25. Paczesny, S., Choi, S., Ferrara, J. (2009). Acute graft-versus-host disease: New treatment strategies. Curr Opin Hematol, 16:427–436.CrossRefPubMedGoogle Scholar
  26. Patriarca, F., Sperotto, A., Damiani, D., Morreale, G., Bonifazi, F., Olivieri, A., et al. (2004). Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica, 89:1352–1359.PubMedGoogle Scholar
  27. Perfetti, P., Carlier, P., Strada, P., Gualandi, F., Occhini, D., Van Lint, M., et al. (2008). Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant, 42:609–617.CrossRefPubMedGoogle Scholar
  28. Pidala, J., Anasetti, C. (2010). Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant, EPUB 2010 JAN 19.Google Scholar
  29. Pilada, J., Kim, J., Anasetti, C. (2009). Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 15:881–885.CrossRefGoogle Scholar
  30. Pinana, J., Valcarcel, D., Martino, R., Moreno, M., Sureda, A., Briones, J., et al. (2006). Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory graft-versus-host disease. Biol Blood Marrow Transplant, 12:1135–1141.CrossRefPubMedGoogle Scholar
  31. Ross, W., Couriel, D. (2004). Colonic graft-versus-host disease. Curr Opin Gastroenterol, 21:64–69.Google Scholar
  32. Rowlings, PA., Przepiorka, D., Klein, JP., Gale, RP., Passweg, JR., Henslee-Downey, PJ., et al. (1997). IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol, 97:855–864.Google Scholar
  33. Scarisbrick, J. (2009). Extracorporeal photopheresis: What is it and when should it be used. Clin Exp Dermatol, 34:757–760.CrossRefPubMedGoogle Scholar
  34. Schmidt-Hieber, M., Fietz, T., Knauf, W., Uharek, L., Hopfenmuller, W., Thiel, E., et al. (2005). Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematology, 130:568–574.CrossRefGoogle Scholar
  35. Shapira, M., Resnick, I., Bitan, M., Ackerstein, A., Tsirigotis, P., Gesundheit, B., et al. (2005). Rapid responses to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: A preliminary report. Bone Marrow Transplant, 36:1097–1101.CrossRefGoogle Scholar
  36. Snover, D., Weisdorf, S., Ramsay, N., McGlave, P., Kersey, J. (1984). Hepatic graft versus host disease: A study of the predictive value of liver biopsy in diagnosis. Hepatology, 4:123–130.CrossRefPubMedGoogle Scholar
  37. Vogelsang, G., Lee, L., Bensen-Kennedy, D. (2003). Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med, 54:29–52.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Susan Slater
    • 1
  1. 1.Center for Hematologic Malignancies, Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science UniversityPortlandUSA

Personalised recommendations